Trial reportLeukemia2015
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.
Trial report in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Momelotinib therapy for myelofibrosis: a 7-year follow-up.Blood cancer journal · 2018Trial
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Blood · 2015Trial
- Targeting the JAK/STAT signalling axis in cancer: chemopreventive potential of natural compounds with emerging focus on retinoids.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Advances in Stem Cell Transplantation for Myelofibrosis.Current hematologic malignancy reports · 2024Review
- Momelotinib for the treatment of myelofibrosis.Blood · 2024Review
- Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.Blood cancer journal · 2024Article
- Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.Haematologica · 2023Article
- Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor.Blood cancer journal · 2023Article
- Management of Myelofibrosis: from Diagnosis to New Target Therapies.Current treatment options in oncology · 2020Review
- Mutant Calreticulin in the Myeloproliferative Neoplasms.HemaSphere · 2020Review
- HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.Blood · 2020Article
- Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.Hematology. American Society of Hematology. Education Program · 2019Review
- Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Article
- Targeted therapies for myeloproliferative neoplasms.Biomarker research · 2019Review
- Article
- Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience.HemaSphere · 2018Article
- JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.F1000Research · 2018Review
- Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.Blood advances · 2017Article
- Pharmacotherapy of Myelofibrosis.Drugs · 2017Review
- Developmental Therapeutics in Myeloproliferative Neoplasms.Clinical lymphoma, myeloma & leukemia · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.